TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2201795
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (10 million units) recombinant alpha‐2b‐interferon
Study: 189334
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ACTH 4-10
Study: 189334
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ACTH 4-10
Study: 31288177
Drug: VEGF-A165/bFGF plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF-A165/bFGF plasmid (VIF) administered via electromechanical system NOGA-guided intramyocardial injections into ischemic regions.
Study: 31288177
Drug: Placebo plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plasmid injections.
Study: 28374466
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) - 156 ml of a mixture of 0.2% ropivacaine + 30 mg ketorolac + 0.5 mg (5 ml) adrenaline
Study: 28374466
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and intravenous ketorolac (Control)
Study: 7582282
Drug: Inhaled wild‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled wild‐type rhinovirus 16 (RV16) administered at a total dose of 3 x 10(4) TCID50
Study: 7582282
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in equal doses into both nostrils
Study: 1782971
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (0.8, 1.6, and 3.2 mg/day)
Study: 1782971
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (5, 10, and 20 mg/day)
Study: 1782971
Drug: Both inhaled
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both inhaled budesonide and oral prednisolone
Study: 28183288
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy (Sp-Tx)
Study: 21963104
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride topical gel (OTG)
Study: 19257867
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy for IHD)
Study: 17907859
Drug: self‐help involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐help involvement during treatment
Study: 17907859
Drug: self‐efficacy and
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐efficacy and commitment to abstinence 3 months after treatment
Study: 9676755
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered intramuscularly at 10 AM
Study: 9676755
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered intramuscularly at 6 PM
Study: 9676755
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of MTX administration times (10 AM vs 6 PM)
Study: 29643163
Drug: Intratracheal Dex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal Dex (0.5 µg/kg)
Study: 29643163
Drug: Intravenous Dex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dex (0.5 µg/kg)
Study: 29643163
Drug: Control (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Intravenous saline)
Study: 28333551
Drug: 6-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week group program of 2-hour weekly sessions addressing mindfulness of food choices facilitated by a trained dietitian and social worker.
Study: 25883031
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human soluble thrombomodulin (rhTM) administration
Study: 25883031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rhTM administration)
Study: 17199537
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) therapy using non-resorbable expanded polytetrafluoroethylene membranes
Study: 17199537
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) therapy using bioabsorbable barriers
Study: 11559318
Drug: Trimethoprim-sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice daily for 2 weeks, followed by 80 mg trimethoprim and 400 mg sulfamethoxazole twice daily for 5.5 months
Study: 3169108
Drug: SR verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR verapamil 240 mg tablets administered every 12 h for 6 consecutive weeks
Study: 3169108
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 12 h for 6 consecutive weeks
Study: 21439962
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition for 30 days
Study: 12738159
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 600 microg
Study: 12738159
Drug: Combined rectal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rectal groups (400 and 600 microg)
Study: 12738159
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (both doses)
Study: 8797943
Drug: Iodixanol (Visipaque,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (Visipaque, 320 mgI/ml)
Study: 8797943
Drug: Iopamidol (Solutrast,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (Solutrast, 370 mgI/ml)
Study: 6237623
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg three times a day
Study: 6237623
Drug: Captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 37.5 mg twice daily
Study: 6237623
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg three times a day
Study: 6822143
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg twice daily
Study: 6237623
Drug: Hydrochlorothiazide and
Normalized name: hydrochlorothiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and Captopril combination
Study: 29447773
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor only
Study: 29447773
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (DAPT + oral anticoagulant)
Study: 29447773
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) only
Study: 29447773
Drug: OAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC plus P2Y12 inhibitor
Study: 29447773
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents without OAC
Study: 25011657
Drug: SMS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS group (received 2 text messages twice a day for 12 weeks)
Study: 22747980
Drug: Intramyocardial CD133(+)
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial CD133(+) bone marrow stem cell injection in combination with coronary artery bypass grafting
Study: 7925204
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide (800 micrograms kg‐1 in two divided doses)
Study: 24366980
Drug: LBR-101 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBR-101 (any dose)
Study: 24366980
Drug: LBR-101 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBR-101 (1000 mg or higher)
Study: 10102953
Drug: Budesonide 15
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 15 mg/day
Study: 10102953
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg/day
Study: 10102953
Drug: Budesonide 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 4.5 mg b.d.
Study: 7805221
Drug: Encainide, flecainide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide, flecainide, and moricizine at two different dose levels (CAST-I); Moricizine alone at three dose levels (CAST-II).
Study: 27246522
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.7 g of long-chain n-3 polyunsaturated fatty acids)
Study: 22935168
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (OLAI)
Study: 14985864
Drug: Standardized uptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized uptake value (SUV) images acquired from 30 to 35 min after FMZ administration
Study: 7653818
Drug: Ropivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (5 mg/mL)
Study: 7653818
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mg/mL)
Study: 314392
Drug: Fenbufen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (500 mg capsules)
Study: 314392
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (750 mg capsules)
Study: 27535352
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg clonidine orally
Study: 26448622
Drug: tPA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA (50 mg Alteplase)
Study: 23357838
Drug: Probenecid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (500 mg 4 times daily for 6 days)
Study: 15679255
Drug: Gemcitabine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (specific dosage and duration not mentioned)
Study: 15679255
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy and gemcitabine (specific details not mentioned)
Study: 8799512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg sublingual
Study: 8799512
Drug: Nifedipine (NIF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NIF) 10 mg
Study: 8799512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg orally twice daily
Study: 8799512
Drug: Nifedipine (NIF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NIF) 20 mg twice daily
Study: 1459316
Drug: benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (10 mg/day)
Study: 15931690
Drug: Oral famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral famciclovir 250 mg twice daily
Study: 11789262
Drug: Composite Taixian
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite Taixian tablet (CTXT)
Study: 11789262
Drug: Tripterygium hypoglaucum
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium hypoglaucum tablet
Study: 11789262
Drug: Polyactin‐A tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyactin‐A tablet
Study: 9081688
Drug: 2 mg/d
Normalized name: Uceris, 2 mg/dose rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/d micronized 17 beta-estradiol
Study: 1608523
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg bid im starting one day before surgery and continuing until the 7th postoperative day)
Study: 1608523
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5000 IU bid sc starting two hours before surgery and continuing likewise for 7 days)
Study: 3936097
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (450 mg)
Study: 3936097
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (900 mg)
Study: 31164265
Drug: Letrozole (L)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (L) vs Tamoxifen (T)
Study: 31164265
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZL) vs Letrozole (L)
Study: 29874375
Drug: Oxaliplatin followed
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin followed by TME and adjuvant chemotherapy (experimental arm)
Study: 31283920
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening (LDCT)
Study: 18710726
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus placebo, oxybutynin, or bladder training with online feedback (urge syndrome)
Study: 18710726
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus pelvic floor training with online feedback (dysfunctional voiding)
Study: 18710726
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (urge syndrome and dysfunctional voiding)
Study: 15972357
Drug: Disease-modifying anti-rheumatic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying anti-rheumatic drug (DMARD) therapy
Study: 12133434
Drug: 6-MWT exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-MWT exercise training (twice a day for 8 weeks)
Study: 12133434
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine medication only)
Study: 10613616
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg estradiol valerate and 0.25 mg levonorgestrel once daily)
Study: 7784306
Drug: Brand 1
Normalized name: Select Brand 12-Hour 0.05% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 1 (Biltricide) at full dose (40 mg kg‐1)
Study: 7784306
Drug: Brand 2
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 2 (Distocide) at full dose (40 mg kg‐1)
Study: 7784306
Drug: Brand 1
Normalized name: Select Brand 12-Hour 0.05% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 1 (Biltricide) at half dose (20 mg kg‐1)
Study: 7784306
Drug: Brand 2
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 2 (Distocide) at half dose (20 mg kg‐1)
Study: 2019862
Drug: Cefodizime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (2 g, once a day, i.v.)
Study: 2019862
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg, twice a day, p.o.)
Study: 6924538
Drug: Two-week amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week amoxicillin treatment (250 mg three times a day)
Study: 21319291
Drug: Opioids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids treatment
Study: 21319291
Drug: Vincristine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine dose
Study: 17972431
Drug: Daily Mutual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Mutual Caring Interactions (DMCI) scale
Study: 7938234
Drug: Phenylalanine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine (up to 10.08 g)
Study: 7938234
Drug: Aspartame (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (high doses)
Study: 3203045
Drug: Nisoldipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (5 mg day-1)
Study: 3203045
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg day-1)
Study: 31313402
Drug: XR-NTX injection
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX injection every 4 weeks
Study: 31313402
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection every 4 weeks
Study: 28410787
Drug: 0.2% NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NTG ointment applied at the anal canal twice daily for 8 weeks
Study: 28410787
Drug: Classical conservative
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical conservative therapy (sitz bath, stool softener, local anesthetic)
Study: 26180222
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 8 weeks of nicotine replacement therapy (NRT) patch
Study: 23549909
Drug: OM 40/AML
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM 40/AML 10/HCTZ 25 mg triple-combination treatment
Study: 18349202
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of dexamethasone i.v. before surgery
Study: 10981070
Drug: Dihydropyridine calcium-channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium-channel blockers
Study: 8877026
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg)
Study: 8877026
Drug: Co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim)
Study: 29650949
Drug: Monoclonal IgG
Normalized name: Monoclonal IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal IgG antibodies against Fel d 1 (single dose)
Study: 24714359
Drug: Erlotinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib therapy
Study: 18377647
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy (EYT) as an add-on treatment
Study: 16153010
Drug: Theophylline ethanoate
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline ethanoate of piperazine suppositories (Minophylline 500 mg)
Study: 16153010
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) theophylline ethanoate of piperazine (Minophylline ampoules 500 mg)
Study: 8697058
Drug: Sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 20 mg/day
Study: 8911510
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with ALT
Study: 26993261
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of renal replacement therapy
Study: 26993261
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of renal replacement therapy
Study: 24332419
Drug: Newer-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer-generation drug-eluting stents (everolimus-eluting stent or biolimus A9-eluting stent)
Study: 20375277
Drug: Low anticoagulant
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anticoagulant 2-O,3-O-desulfated heparin (ODSH)
Study: 17493184
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided from admission to discharge by a specialist clinical pharmacist
Study: 11486702
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 (conventional dose)
Study: 11486702
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2 (intensive dose)
Study: 31465092
Drug: AAV2-REP1 gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10^11 genome particles)
Study: 24954781
Drug: Sequential chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoimmunotherapy (chemotherapy with sequential GV1001)
Study: 24954781
Drug: Concurrent chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoimmunotherapy (chemotherapy with concurrent GV1001)
Study: 22224877
Drug: Community-focused interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-focused interventions (e.g., school-based programs, community coalitions)
Study: 19008007
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) therapy
Study: 19008007
Drug: Rosiglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone plus insulin (INS+RSG)
Study: 19008007
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (INS)
Study: 15500597
Drug: Buprenorphine (58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (58 mg subcutaneous depot injection)
Study: 10667832
Drug: Dexibuprofen 400
Normalized name: Dexibuprofen 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 400 mg t.i.d.
Study: 10667832
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 800 mg t.i.d.
Study: 11771571
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 2400 mg daily